KURAKura Oncology, Inc.
Price
+11%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 10% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for KURA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Charts
As reported to the SEC, without any scoring.
Kura Oncology, Inc. (KURA) reported revenue of $21M in Q2 2026 (quarter ended Jun 30, 2026), up 37% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $68M. For the full year FY2025, revenue was $67M (+25% year on year) and net income −$279M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer …Director or officer change · Form 8-K
- Aug 12, 2026Kura Oncology Reports SECOND Quarter 2026 Financial Results.Earnings release · press release
- Jul 29, 2026On July 24, 2026, Kura Oncology, Inc. (the “Company”) entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer (the “Wilson Agreement”) to, among other things, modify certain severance provisions.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.